Loading clinical trials...

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE3

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT06323356•Takeda

View on ClinicalTrials.gov

Summary

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. A diagnosis of GPP or EP prior to the screening visit.
•2. Candidate for phototherapy or systemic therapy.

Exclusion Criteria

•1. Other forms of psoriasis.
•2. History of recent infection.
•3. Any prior exposure to TAK-279, or participation in any study that included a TYK2 inhibitor.

Locations (20)

Nagoya City University Hospital

Nagoya, Aichi-ken, Japan

Fujita Health University Hospital

Toyoake, Aichi-ken, Japan

Kimitsu Chuo Hospital

Kisarazu, Chiba, Japan

Juntendo University Urayasu Hospital

Urayasu, Chiba, Japan

Hospital of the University of Occupational and Environmental Health, Japan

Kitakyushu, Fukuoka, Japan

Isesaki Municipal Hospital

Isesaki, Gunma, Japan

Kobe University Hospital

Kobe, Hyōgo, Japan

Tokai University Hospital

Isehara, Kanagawa, Japan

Mie University Hospital

Tsu, Mie-ken, Japan

Kansai Medical University Hospital

Hirakata, Osaka, Japan

Key Dates

Start Date

March 19, 2024

Primary Completion Date

October 15, 2025

Completion Date

July 22, 2026

Last Updated

November 17, 2025

Enrollment

ACTUAL participants

Conditions

Generalized Pustular PsoriasisErythrodermic Psoriasis

Interventions

TAK-279

DRUG

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

NCT06477536

Generalized Pustular Psoriasis

View study

NOT_YET_RECRUITING

Generalized Pustular Psoriasis Registry in Costa Rica

NCT07448428

Generalized Pustular PsoriasisGeneralized Pustular Psoriasis (GPP)

View study

NOT_YET_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Inclusion Criteria

Exclusion Criteria

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

Generalized Pustular Psoriasis Registry in Costa Rica

Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis